INS and cancer: Despite evidence of direct actions on signaling pathways in pancreatic cells, we cannot rule out that indirect, systemic effects of the combination of metformin and simvastatin (e.g. effects on insulin sensitivity, gut microbiome, or lipid metabolism18) also contribute to the beneficial effects on pancreatic fibro-inflammation and cancer development in our study.